<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Pharma — Oktober 2022]]></title><description><![CDATA[<p dir="auto">The Top Healthcare Stock to Buy With $100 <a href="https://www.proinvestor.com/investornyt/888176/the-top-healthcare-stock-to-buy-with-100" rel="nofollow ugc">https://www.proinvestor.com/investornyt/888176/the-top-healthcare-stock-to-buy-with-100</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/400867/pharma-oktober-2022</link><generator>RSS for Node</generator><lastBuildDate>Sun, 07 Jun 2026 11:20:05 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/400867.rss" rel="self" type="application/rss+xml"/><pubDate>Sat, 08 Oct 2022 13:14:12 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Pharma — Oktober 2022 on Tue, 25 Oct 2022 05:04:05 GMT]]></title><description><![CDATA[<p dir="auto">AstraZeneca: Fasenra Trial In EoE Did Not Meet One Of Two Dual-primary Endpointshttps://www.proinvestor.com/investornyt/894601/astrazeneca-fasenra-trial-in-eoe-did-not-meet-one-of-two-dual-primary-endpoints</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037633</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037633</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 25 Oct 2022 05:04:05 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Oktober 2022 on Tue, 25 Oct 2022 04:17:39 GMT]]></title><description><![CDATA[<p dir="auto">Novartis Q3 Core Operating Income Up 5% In Constant Currency, Sales Up 4%; Confirms Group Guidance <a href="https://www.proinvestor.com/investornyt/894588/novartis-q3-core-operating-income-up-5-in-constant-currency-sales-up-4-confirms-group-guidance" rel="nofollow ugc">https://www.proinvestor.com/investornyt/894588/novartis-q3-core-operating-income-up-5-in-constant-currency-sales-up-4-confirms-group-guidance</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037630</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037630</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 25 Oct 2022 04:17:39 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Oktober 2022 on Tue, 25 Oct 2022 03:56:15 GMT]]></title><description><![CDATA[<p dir="auto">Test</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037631</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037631</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 25 Oct 2022 03:56:15 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Oktober 2022 on Tue, 18 Oct 2022 03:11:12 GMT]]></title><description><![CDATA[<p dir="auto">Lundbeck/Jefferies: Kursmål sænket på bekymring for aktiefrasalg <a href="https://www.proinvestor.com/investornyt/891549/lundbeck-jefferies-kursmal-saenket-pa-bekymring-for-aktiefrasalg-ny" rel="nofollow ugc">https://www.proinvestor.com/investornyt/891549/lundbeck-jefferies-kursmal-saenket-pa-bekymring-for-aktiefrasalg-ny</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037632</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037632</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 18 Oct 2022 03:11:12 GMT</pubDate></item></channel></rss>